Acadia Pharmaceuticals
Robert Hofbauer is the Executive Director, Clinical Science at Acadia Pharmaceuticals Inc., responsible for leading the strategy and tactics for the pimavanserin autism program. With a background in neurological sciences and psychology, Robert has held various senior roles in clinical development at companies like Mitsubishi Tanabe Pharma Development America and Turing Pharmaceuticals AG. As a Principal Consultant at Surmount Pharma Consulting, Robert provides clinical development consulting services to the pharmaceutical and biotechnology industry. Throughout their career, Robert has demonstrated expertise in leading clinical trial operations, managing early development projects, and overseeing clinical development programs for orphan indications in CNS and infectious disease.
This person is not in any offices
Acadia Pharmaceuticals
3 followers
Acadia is trailblazing breakthroughs in neuroscience to elevate life. They are at the forefront of healthcare, fighting for breakthroughs in our science, their therapies and the way we work, but also in the lives of the people they serve. Acadia is committed to their purpose: we fight disease so more you shines through.